Out of Hospital Antithrombotic Prophylaxis after Total Hip Replacement: Low-molecular-weight Heparin, Warfarin, Aspirin or Nothing?

Summary

Several studies have suggested that after hip replacement the risk of deep vein thrombosis and subsequent pulmonary embolism (PE) may persist for some weeks. Antithrombotic prophylaxis, however, is generally stopped at hospital discharge. Using a Markov-based decision analysis, we measured the clinical and economical consequences of extending prophylaxis after hospital discharge up to 4 weeks and 6 weeks, using either low-molecular-weight heparin (LMWH), warfarin, or aspirin. In the reference strategy, antithrombotic prophylaxis was stopped at hospital discharge. Outcome measures included the number of PE prevented, major haemorrhages induced, overall costs in Euro (EUR) and specific costs generated by each PE prevented for all strategies.

Extending prophylaxis up to 4 weeks after discharge was safe and cost saving for all prophylactic regimens, although LMWH was the most effective strategy. Our results were most sensitive to the rate of haemorrhages, the efficacy of treatment and its costs. Specifically, the number of PEs prevented exceeded that of haemorrhages induced if the efficacy of antithrombotic prophylaxis was 2:40% (assuming a low rate of haemorrhages of 0.1% per week), and 2:70% (assuming a high rate of haemorrhages of 0.25% per week). LMWH and warfarin remained cost saving unless their costs were more than doubled compared to that of baseline value. Although less effective than LMWH and warfarin, prophylaxis with aspirin was cost saving in all scenarios tested. Extending prophylaxis up to 6 weeks was also effective (the number of PEs prevented overwhelmed that of major haemorrhages induced), but only for the scenario of a low bleeding risk (0.1%/week). In this strategy, aspirin remained cost saving, while the costs for each PE prevented became high (EUR 10,000 to EUR 20,000) if the costs of LMWH and warfarin increased.

After hip replacement, extending antithrombotic prophylaxis up to 4 weeks after hospital discharge is effective and cost saving. Although LMWH is the most effective strategy, warfarin, and to a lesser extent aspirin may be alternate options if ressources are a major concern.

Extending prophylaxis up to 6 weeks is more risky in patients at high bleeding risk, and generates additional costs.

Keywords

Deep vein thrombosis - hip replacement - antithrombotic prophylaxis - cost-effectiveness

• References

• 1 Claggett GP, Anderson FA, Geerts W, Heit JA, Knudson M, Lieberman JR. et al. Prevention of venous thromboembolism. Fifth ACCP Consensus Conference on Antithrombotic Therapy. Chest 1998; 114 (Suppl): 531S-560S.
• 2 Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. N Engl J Med 1988; 318: 1162-73.
• 3 Leizorovicz A, Haugh MC, Chapuis FR, Samama MM, Boissel JP. Low molecular weight heparin in prevention of perioperative thrombosis. BMJ 1992; 305: 913-20.
• 4 Anderson DR, O’Brien BJ, Levine MN, Roberts R, Wells PS, Hirsh J. Efficacy and cost of low-molecular-weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty. Ann Intern Med 1993; 119: 1105-12.
• 5 Planes A, Vochelle N, Darmon JY, Fagola M, Bellaud M, Huet Y. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip arthroplasty: double-blind randomised comparison of enoxaparin versus placebo. Lancet 1996; 348: 224-8.
• 6 Bergqvist D, Benoni G, Bjorgell O, Fredin H, Hedlundh U, Nicolas S, Nilsson P, Nylander G. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 1996; 335: 696-700.
• 7 Huber O, Bounameaux H, Borst F, Rohner A. Postoperative pulmonary embolism after hospital discharge: an underestimated risk. Arch Surg 1992; 127: 310-3.
• 8 Johnson R, Carmichael JHE, Almond HGA, Loynes RP. Deep venous thrombosis following Charnley arthroplasty. Clin Orthop 1978; 132: 24-30.
• 9 Johnson R, Gree JR, Charnley J. Pulmonary embolism and its prophylaxis following the Charnley total hip replacement. Clin Orthop 1977; 127: 123-32.
• 10 Kakkar VV, Fok PJ, Murray WJ, Paes T, Merenstein D, Dodds R. et al. Heparin and dihydroergotamine prophylaxis against thrombo-embolism after hip arthroplasty. J Bone Joint Surg 1985; 67B: 538-42.
• 11 Sikorski JM, Hampson WG, Staddon GE. The natural history and etiology of deep vein thrombosis after hip replacement. J Bone Joint Surg 1981; 63B: 171-7.
• 12 Sarasin FP, Bounameaux H. Antithrombotic strategy after total hip replacement: a cost-effectiveness analysis comparing prolonged oral anticoagulants with screening for deep vein thrombosis. Arch Intern Med 1996; 156: 1661-8.
• 13 Lassen MR, Borris LC, Anderson BS, Jensen HP, Skejo HPBro, Andersen G. et al Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty - the Danish Prolonged Prophylaxis (DaPP) Study. Thromb Res 1998; 89: 281-7.
• 14 Dahl OE, Andreassen G, Aspelin T, Muller C, Mathiesen P, Hyhus S. et al. Prolonged thromboprophylaxis following hip replacement surgery - results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin. Thromb Haemost 1997; 77: 26-31.
• 15 Hull RD, Pineo GF, Francis C, Bergqvist D, Fellenius C, Soderberg K. et al. Low-molecular weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial Investigators. Arch Intern Med 2000; 160: 2208-15.
• 16 Pulmonary Embolism Prevention (PEP) Trial Collaborative Group. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 2000; 355: 1295-302.
• 17 Sonnenberg FA, Pauker SG, Kassirer JP. Decision Maker 7.0. Boston, Mass: Pratt Medical Group; 1991
• 18 Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Dec Making 1993; 13: 322-8.
• 19 Lagerstedt CL, Olsson CG, Fagher BO, Öquist BW, Albrechtsson U. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet 1985; 02: 515-8.
• 20 Beisaw NE, Comerota AJ, Groth HE. et al. Dihydroergotamine/heparin in the prevention of deep-vein thrombosis after hip replacement: a controlled, prospective randomized multicenter trial. J Bone Joint Surg 1988; 70: 2-10.
• 21 Hoeck JA, Nurmohamed MT, Hamelynck RJ. et al. Prevention of deep vein thrombosis following total hip replacement by low molecular weight heparinoid. Thromb Haemost 1992; 67: 28-32.
• 22 Hull RD, Raskob GE, Gent M. et al. Effectiveness of intermittent pneumatic leg compression for preventing deep vein thrombosis after total hip replacement. JAMA 1990; 263: 2313-7.
• 23 Lassen MR, Borris LC, Christiansen HM. et al. Prevention of thromboembolism in 190 hip arthroplasties: comparison of LMW heparin and placebo. Acta Orthop Scand 1991; 62: 33-8.
• 24 Hull R, Delmore T, Genton E. et al. Warfarin sodium versus low-dose heparin in the treatment of venous thrombosis. N Engl J Med 1979; 301: 855-8.
• 25 Schulman S, Lockner D, Juhlin-Dannfelt A. The duration of oral anticoagulation after deep vein thrombosis. Acta Med Scand 1985; 217: 547-52.
• 26 Holmgren K, Andersson G, Fagrell B. et al. One-month versus six-month therapy with oral anticoagulants after symptomatic deep vein thrombosis. Acta Med Scand 1985; 218: 279-84.
• 27 Hull RD, Delmore T, Carter C. et al. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med 1982; 306: 189-94.
• 28 Hull RD, Hirsh J, Carter C. et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 1982; 307: 1676-81.
• 29 Sarasin FP, Bounameaux H. Duration of oral anticoagulant therapy after proximal deep vein thrombosis: a decision analysis. Thromb Haemost 1994; 71: 286-91.
• 30 Hyers TM. Venous thromboembolism. Am J Resp Crit Care Med 1999; 159: 1-14.
• 31 Levine MN, Raskob G, Landefeld SC, Kearon C. Hemorrhagic complications of anticoagulant treatment. Fifth ACCP Consensus Conference on Antithrombotic Therapy. Chest 1998; 114 (Suppl): 511S-523S.
• 32 Hull RD, Pineo GF, Stein PD, Mah AF, MacIsaac SM, Dahl OE. et al. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med 2001; 135: 858-69.
• 33 Menzin J, Colditz GA, Regan MM, Richner RE, Oster G. Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep vein thrombosis after total hip replacement surgery. Arch Intern Med 1995; 155: 757-64.
• 34 Oudkerk M, van Beek EJR, van Putten WLJ, B¸ller HR. Cost-effectiveness analysis of various strategies in the diagnostic management of pulmonary embolism. Arch Intern Med 1993; 153: 947-54.
• 35 Antiplatelet Trialists’ Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ 1994; 308: 235-46.
• 36 Heit JA, Elliott CG, Trowbridge AA, Morrey BF, Gent M, Hirsh J. for the Ardeparin Arthroplasty Study Group. Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2000; 132: 853-61.